These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7357525)

  • 1. Variation of microsomal mixed function oxidase(s) and human lung cancer.
    Kellermann G; Jett JR; Luyten-Kellermann M; Moses HL; Fontana RS
    Cancer; 1980 Mar; 45(6):1438-42. PubMed ID: 7357525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipyrine metabolism in lung cancer patients and their relatives.
    Radzikowska E; Gazdzik W; Rowińska-Zakrzewska E
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():297-308. PubMed ID: 9337547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of seasonal variation in antipyrine metabolism.
    Paigen B; Ward E; Steenland K; Bolanowska W; Gessner T; Chang RL; Wood AW; Conney AH
    Clin Pharmacol Ther; 1982 Feb; 31(2):144-50. PubMed ID: 7056021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipyrine clearance and metabolism in patients with psoriasis.
    Kubota K; Ishizaki T; Chiba K; Takagi A; Nakagawa A; Nakamura K
    Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzo(a)pyrene metabolism and plasma elimination rates of phenacetin, acetanilide and theophylline in man.
    Kellermann G; Luyten-Kellermann M
    Pharmacology; 1978; 17(4):191-200. PubMed ID: 693568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.
    Pelkonen O; Sotaniemi E; Tokola O; Ahokas JT
    Drug Metab Dispos; 1980; 8(4):218-22. PubMed ID: 6105054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic microsomal drug metabolism, glutamyl transferase activity and in vivo antipyrine half-life in rats chronically fed an ethanol diet, a control diet and a chow diet.
    Gadeholt G; Aarbakke J; Dybing E; Sjöblom M; Mørland J
    J Pharmacol Exp Ther; 1980 Apr; 213(1):196-203. PubMed ID: 6102148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates for antipyrine and phenylbutazone.
    Kellermann G; Luyten-Kellermann M; Horning M; Stafford M
    Drug Metab Dispos; 1975; 3(1):47-50. PubMed ID: 234834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of drug metabolism in rats exposed to cigarette smoke.
    Farrell GC; Cooksley WG; Cash GA; Powell LW
    Aust J Exp Biol Med Sci; 1980 Dec; 58(6):585-90. PubMed ID: 7271596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary disease and antipyrine clearance.
    Laybourn C; Tønnesen P; Loft S; Sonne J; Døssing M
    Clin Pharmacol Ther; 1986 Oct; 40(4):415-9. PubMed ID: 3489577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of hepatic aryl hydrocarbon hydroxylase activity in feral winter flounder: relevance to carcinogenicity testing.
    Bend JR; Foureman GL; Ben-Zvi Z; Albro PW
    Natl Cancer Inst Monogr; 1984 May; 65():359-70. PubMed ID: 6462197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolism of antipyrine in man].
    Pautet F; Barret R; Daudon M; Mathian B
    Pathol Biol (Paris); 1985 Sep; 33(7):777-80. PubMed ID: 3909077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.
    Farrell GC; Cooksley WG; Powell LW
    Clin Pharmacol Ther; 1979 Oct; 26(4):483-92. PubMed ID: 487696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between antipyrine and aminopyrine.
    Vesell ES; Passananti GT; Hepner GW
    Clin Pharmacol Ther; 1976 Dec; 20(6):661-9. PubMed ID: 991537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a non-steroid anti-inflammatory agent on the drug metabolizing activity of the human liver.
    Gachályi B; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):353-4. PubMed ID: 6469424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disposition of antipyrine in patients with lung cancer.
    Tschanz C; Hignite CE; Huffman DH; Azarnoff DL
    Cancer Res; 1977 Nov; 37(11):3881-6. PubMed ID: 908027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aryl hydrocarbon hydroxylase in man and lung cancer.
    Kellermann G; Luyten-Kellermann M; Jett JR; Moses HL; Fontana RS
    Hum Genet Suppl; 1978; (1):161-8. PubMed ID: 285027
    [No Abstract]   [Full Text] [Related]  

  • 20. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.
    Boobis AR; Brodie MJ; Kahn GC; Fletcher DR; Saunders JH; Davies DS
    Br J Clin Pharmacol; 1980 Jan; 9(1):11-9. PubMed ID: 6766729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.